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Background
The rapid development of nanotechnology is of great interest to researchers focused 
on translational medicine and novel targeted cancer treatment (Kim et  al. 2010). 
The most popular applications of nanotherapeutics include diagnosis and treatment 
Abstract 
Background: The first‑line chemotherapy drug that is used to treat pancreatic ductal 
adenocarcinoma is gemcitabine. Unfortunately, its effectiveness is hampered by its 
chemo‑resistance, low vascularization and drug biodistribution limitations in the tumor 
microenvironment. Novel nanotherapeutics must be developed in order to improve 
the prognosis for patients with pancreatic cancer.
Results: We developed a synthetic methodology for obtaining a water‑soluble nano‑
conjugate of a [60]fullerene‑glycine derivative with the FDA‑approved drug gemcit‑
abine (nanoC60GEM). The proposed synthetic protocol enables a highly water‑soluble 
[60]fullerene‑glycine derivative (6) to be obtained, which was next successfully conju‑
gated with gemcitabine using the EDCI/NHS carbodiimide protocol. The desired nano‑
conjugate was characterized using mass spectrometry and DLS, IR and XPS techniques.
The photogeneration of singlet oxygen and the superoxide anion radical were studied
by measuring 1O2 near‑infrared luminescence at 1270 nm, followed by spin trapping
of the DMPO adducts by EPR spectroscopy. The biological assays that were performed 
indicate that there is an inhibition of the cell cycle in the S phase and the induction of 
apoptosis by  nanoC60GEM.
Conclusion: In this paper, we present a robust approach for synthesizing a highly 
water‑soluble [60]fullerene nanoconjugate with gemcitabine. The performed biological 
assays on pancreatic cancer cell lines demonstrated cytotoxic effects of  nanoC60GEM, 
which were enhanced by the generation of reactive oxygen species after blue LED 
irradiation of synthesized fullerene nanomaterial.
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of cancer, targeted drug delivery systems and in  vivo imaging (Chow and Ho 2013; 
Dawidczyk et  al. 2014). The nanotechnology approach has been used by medicinal 
chemists to design potential drugs that can easily break through almost any biological 
barrier. Engineered nanoparticles, including carbon nanomaterials, can enter tumors 
via their leaky vessels and remain there due to the weak drainage in the tumor micro-
environment. This phenomenon is called the enhanced permeability and retention 
effect (EPR effect) and does not occur in normal tissues (Fang et al. 2011; Maeda et al. 
2016). Interestingly, in our recently published article, we demonstrated that fluores-
cently labeled fullerenes (C ⁠60-serPF) can be used as a model delivery system for bio-
distribution studies in a breast cancer model, due to their preferred biokinetic profile 
(Lapin et al. 2017a).
Since their discovery in 1985, fullerene nanomaterials have drawn the attention of 
medicinal chemists due to their unique biological properties (Nakamura and Isobe 
2003). Over the last few decades, [60]fullerenes have been investigated for many bio-
medical applications, including targeted drug delivery, and as contrast agents and non-
viral transfection agents (Dellinger et  al. 2013). The functionalization of the fullerene 
cage with water solubilizing groups offers a versatile method for biological experiments, 
as well as for conjugation with chemotherapeutic agents, fluorescent probes and cancer-
targeting antibodies (Zakharian et al. 2005; Ashcroft et al. 2006). Appropriately derivat-
ized [60]fullerene buckyballs become amphiphilic in nature with the ability to cross most 
biological barriers, including the blood–brain barrier and nuclear membrane (Raoof 
et  al. 2012). Furthermore, fullerene nanomaterials are non-toxic even at high concen-
trations of up to 1 mg/mL (Serda et al. 2018). The anti-cancer activity of fullerenes has 
mainly been described for in vivo models, where it has been explained by its ability to 
inhibit tumor angiogenesis (metalloproteinases inhibitors) and its strong antioxidant 
properties (Chen et  al. 2005; Sun et  al. 2016). Interestingly, it was described earlier 
that water-soluble fullerene derivatives have the ability to resensitize cancer cells that 
were previously resistant to cisplatin and doxorubicin (Zhang et al. 2009). The chemi-
cal functionalization of [60]fullerene using the cyclopropanation reaction, in which the 
derivatives of malonic acid are particularly useful (Bingel–Hirsch reaction), offers novel 
synthetic possibilities because it allows virtually any imaginable type of organic moiety 
to be covalently linked to the carbon shell of hydrophobic [60]fullerene.
Pancreatic cancer is a highly lethal disease that has a 5-year survival rate of less than 
10% (Siegel et al. 2015). Currently, the most successful treatment is the surgical resec-
tion of the tumor, but in many cases, it is not possible to perform the surgery because 
only 20% of patients have resectable pancreatic cancer (Kamisawa et al. 2016). Thus, the 
development of non-surgical treatments, including adjuvant therapy, is needed in order 
to improve the prognosis for patients with pancreatic cancer. The first line of chemo-
therapeutic drugs that was used to treat pancreatic cancer was gemcitabine. The clinical 
trials that have been performed have shown that patients with advanced pancreatic can-
cer have better survival rates and durations after treatment with gemcitabine compared 
to those that were treated with 5-fluorouracil (Burris et al. 1997). Moreover, combina-
tions of gemcitabine and different chemotherapeutic agents as well as monoclonal anti-
bodies have also been studied for advanced breast cancer (Hu et al. 2015). Nevertheless, 
the usefulness of the current strategies and the effects of gemcitabine monotherapy are 
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hampered by its chemo-resistance, low vascularization and drug biodistribution limita-
tions in the tumor microenvironment (Kleeff et al. 2007; Koay et al. 2014).
The use of nanoscale drugs that are designed to treat pancreatic tumors have been 
widely explored in the last 5 years, which has resulted in Abraxane, a nano-formulation 
of paclitaxel with albumin (Lee et al. 2013; Pan et al. 2015). Here, we report on a syn-
thetic protocol that enables a water-soluble [60]fullerene nanoconjugate with gemcit-
abine (called nanoC60GEM) to be generated.
Materials and methods
Materials
All of the compounds that were used were reagent grade or better, and the solvents 
were used as they were received unless otherwise specified. The following reagents were 
used as received:  C60 (99.5%, SES RESEARCH, USA), gemcitabine (Sigma Aldrich), 
2-amino-1,3-propanediol (AK Scientific), DBU (1,8-diaza-bicyclo[5.4.0]undec-7-ene, 
Sigma Aldrich), glycine (POCH, Poland), p-toluenesulfonic acid (POCH, Poland), ace-
tic anhydride (Acros Organics), malonic acid (Acros Organics),  CBr4 (Sigma Aldrich), 
EDCI hydrochloride [N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride, 
Acros Organics], N-hydroxysuccinimide (Sigma Aldrich) and sodium hydride (Acros 
Organics). All of the solvents that were used to prepare the carbon nanomaterials were 
prepared according to literature procedures by distilling them with calcium hydride 
and were used immediately. The nuclear magnetic resonance spectra were measured 
on a Bruker Avance III 500  MHz NMR Spectrometer with TMS as the internal stand-
ard. The MS spectra for the water-insoluble fullerenes were collected using an Autoflex 
II MALDI-TOF mass spectrometer, and for the water-soluble [60]fullerene derivatives 
using an MS electrospray ionization time-of-flight (ESI-microTOF) mass spectrom-
eter, both instruments from Bruker Daltonics Inc (Fremont, CA, USA). The final dialy-
sis purification of the water-soluble nanomaterial nanoC60GEM was performed on Pall 
Microsep™ centrifugal membranes with molecular cut-offs 1 and 3 kDa. The purity of all 
of the compounds was assessed using an Agilent1260 equipped with a DAAD detector 
at 260 nm, RP-column: Eclipse plus C18 (3,5 μm); flow 0.5 mL/min. The Fourier trans-
form infrared (FTIR) measurements were carried out using an Agilent Cary 640 FTIR 
spectrometer equipped with a standard source and a DTGS Peltier-cooled detector. The 
nanoconjugate powder was mixed with KBr and measured in the transmittance mode 
in the 700–4000  cm−1 range. The spectrum was  recorded at 32 accumulations with a 
spectral resolution of 4 cm−1. The obtained data were analyzed by the baseline, water, 
and carbon dioxide correction. The chemical analysis of the sample surface was per-
formed using X-ray photoelectron spectroscopy (XPS). The measurements were per-
formed on a PHI5700 Physical Electronics spectrometer. The XPS studies were carried 
out with using an Al Kα monochromatized X-ray source (hν  =  1486.6 eV). The survey 
spectrum was measured at pass energy 187.75e eV, and the high-resolution core levels 
of C1s, F1s, N1s, O1s and Si2 were measured at pass energy 23.5  eV. The analysis of 
the chemical states of the detected elements, as well as the calculations of the atomic 
concentration was performed using MULTIPAK (version 9.6.7.1, 2015, Ulvac-phi Inc.) 
software. The near-infrared luminescence (1270 nm) was measured perpendicular to the 
excitation beam in the photon-counting mode using a thermoelectric-cooled NIR PMT 
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module (H10330-45; Hamamatsu, Japan) equipped with a 1100 nm cut-off filter and an 
additional dichroic narrow-band filter NBP, and was selectable from the spectral range 
1150–1355  nm (NDC Infrared Engineering Ltd., Essex, UK). The data were collected 
using a computer-mounted PCI-board multichannel scaler (NanoHarp 250; PicoQuant 
GmbH, Berlin, Germany). Data analysis, including the first-order luminescence decay 
fitted using the Levenberg–Marquardt algorithm, was performed by custom-written 
software. The acquisition time for obtaining the singlet oxygen phosphorescence signals 
was 20 s. The EPR measurements were taken using a Bruker EMX-AA EPR spectrom-
eter (Bruker BioSpin, Rheinstetten, Germany). EPR samples were run using microwave 
power of 10.6 mW, a modulation amplitude of 0.05 mT, center field 339.0 mT, scan width 
8 mT and scan time 21 s. The light for photodynamic therapy was delivered from royal 
blue 100 W COB source (440 nm, FWHM 17.4 nm) (Chanzon, Shenzhen, China). The 
cell plate was placed in a holder above light source. Distance from the lens was set to 
achieve high uniformity of light power distribution on whole plate area. The cells were 
irradiated with 20 mW/cm2 for 1000 s for a total dose of 20 J. Temperature of cells dur-
ing irradiation did not exceed 32 °C.
Methods
Synthesis of  nanoC60GEM
2,2′-[(1,3-Dioxopropane-1,3-diyl)diimino]diacetic acid or malonyl-diglycine (1).
Glycine (9.75 g, 0.130 mol) was suspended in of 10 mL water and dissolved by adding 
NaOH to the solution (5.21 g, 0.130 mol). A solution of diethyl malonate in 30 mL of 
ethanol (10.4 g, 0.065 mol) was added and the whole mixture was placed in a 100-mL 
flask and heated under reflux for 3 h. The solvent was then removed on a rotary evapo-
rator. Then, 12 M hydrochloric acid was being added to the residue until the pH of the 
mixture reached 1. The flask with the mixture was placed in a refrigerator for 12 h; dur-
ing which the product precipitated. The resulting white solid was filtered off, washed 
with cold water and ethanol and dried. The final product was obtained as a white solid 
with a 19% yield (2.83 g) with m.p. 233 °C.
1H-NMR (d6-DMSO, 400 MHz, ppm): 8.35(t, J = 5.8 Hz, 2H, NH); 3.78(d, J = 5.8 Hz, 
4H,  CH2–NH); 3.17 (s, 2H, –CO–CH2–CO).
13C-NMR  (d6-DMSO, 100 MHz, ppm): 171.5; 167.5; 42.9; 42.7; 41.2.
Diethyl 2,2′-[(1,3-dioxopropane-1,3-diyl)diimino]diacetate or diethyl malonyl-diglyci-
nate (2).
Compound 1 (8.00 g, 36.67 mmol) was dissolved in 150 mL of ethanol and 348.8 mg 
(1.83  mmol, 5% molar ratio) of p-toluenesulfonic acid monohydrate was added. The 
reaction mixture was heated under reflux for 90 h). The solvents were then removed on 
a rotary evaporator to form solidifying oil. This product was purified using the extrac-
tion technique (DCM:NaHCO3 solution). The organic phase was dried using anhydrous 
 CaCl2 and evaporated in vacuo to form a slightly yellowish oil. The final product was 
obtained with an 80% yield (8.09 g).
1H-NMR (d6-DMSO, 500 MHz, ppm): 8.44 (t, J = 5.7 Hz, 2H, NH);4.09 (m, 4H,  CH2–
CH3); 3.85(d, J = 5.7 Hz, 4H,  CH2–NH); 3.18(bs, 2H, –CO–CH2–CO); 1.18(t, J = 7 Hz, 
6H,  CH3).
13C-NMR (d6-DMSO, 125 MHz, ppm): 170.1; 167.6; 61.0; 42.9; 42.5; 41.3; 14.4, 14.3
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Synthesis of diserinol malonate acetate (3)
Diserinol malonate and its peracetylated version were synthesized on a large scale 
using a modified protocol (Serda et al. 2018). Briefly, 2-amino-1,3-propanediol (100 g, 
1076 mmol) and dimethyl malonate (57.4 mL, 500 mmol) were dissolved in dry isopro-
panol, heated with vigorous stirring at 50 °C for 30 min and then stirred at room tem-
perature, under a nitrogen atmosphere for 14 days. After that time, the solid precipitate 
was filtered off and washed with cold isopropanol. After recrystallization from isopro-
pyl alcohol, the white solid was obtained and dried under lyophilization (m.p. 132  °C, 
yield 92%). Serinol malonate (25.0 g, 99.9 mmol) was suspended in pyridine (100 mL, 
1240 mmol) at 0 °C, to which acetic anhydride (150 mL, 1590 mmol) was added drop-
wise over the course of an hour. After reaching 25 °C, dissolution occurred and the solu-
tion was stirred continuously for 48 h. At 0 °C, methanol (50 mL, 1225 mmol) was added 
to quench the remaining acetic anhydride and the solution was stirred for 1  h, after 
which the solvents were removed in vacuo and the residue (yellow oil) was dissolved 
in dichloromethane and recrystallized for 12 h in hexane. The precipitate was collected 
as white crystals via filtration, washed with hexane and dried in vacuo (m.p. 91 °C, lit. 
91–92 °C (Clark et al. 1972)).
[60]Fullerene hexakis adduct (6)
The  C60 (360 mg, 0.500 mol) was added to a freshly distilled toluene (400 mL), mixed 
for 20  min using a magnetic stirrer and suspended using an ultrasonic bath. Then, 
 CBr4  (248.7  mg, 0.75  mmol) and malonate 2 (137.1  mg, 0.500  mmol), both of which 
were suspended in dichloromethane (7 mL), were added. Next, 1,8-diazabicyclo[5.4.0]
undec-7-ene (DBU, 95.1  mg, 0.625  mmol) in 5  mL of DCM was added and the reac-
tion was allowed to proceed for 3 h at room temperature. The final product was isolated 
using the flash chromatography technique, (silica: Mallinckrodt, 75–250  μm particles, 
150 Å pore size). The unreacted residue and impurities were removed with toluene and 
dichloromethane and then the product was eluted with  CH2Cl2:MeOH 5:1 (240  mL) 
and  CH2Cl2:MeOH 2:1 (225 mL) mixtures. The dark brown filtrate was evaporated in 
vacuo to form a brown solid (powder). This final product was obtained with a 64% yield 
(315 mg) and the mass was confirmed using MALDI-TOF (Additional file 1: Fig. S1). The 
obtained monoadduct 4 (183  mg, 0.184  mmol), diserinol malonate acetate (771.1  mg, 
1.843 mmol) and  CBr4  (1222.3 mg, 3.686 mmol) were dissolved in 20 mL of DCM; to 
which 170 mL of freshly distilled toluene was added and stirred for 5 min. Next, 1,8-diaz-
abicyclo[5.4.0]undec-7-ene (DBU, 337 mg, 2.212 mmol) in dichloromethane (3 mL) was 
added slowly over the course of 4 h and the reaction was allowed to proceed with mix-
ing at room temperature for 34 h. Flash chromatography was used (silica: Mallinckrodt, 
75–250 μm particles, 150 Å pore size) to isolate the hexakis product. The unreacted resi-
due and some of the impurities were removed with toluene and dichloromethane and 
then the product was eluted with a  CH2Cl2:MeOH 5:1 (360  mL) mixture. The brown 
filtrate was evaporated (100 mL flask) in vacuo to form a dark brown grease (2.003 g), 
which was hydrolysed in order to obtain unprotected derivative 6. For this purpose, the 
protected [60]fullerene derivative 5 (1.966 g) was dissolved in 20 mL of dry DCM and 
then sodium hydride (200.0 mg, 8.33 mmol) was carefully added in portions and stirred 
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for 15 min. Next, methanol was added (8 mL, in portions of 0.2–0.5 mL) and during this 
period, intense bubbling was observed (at the bottom of the flask, however, unreacted 
so it remained). The flask was tightly closed and the reaction with mixing was allowed 
to proceed at room temperature for 60 h. Then, 1.5 mL of methanol was added to the 
brown mixture in the flask; no bubbling was observed. The solvents were evaporated 
in vacuo to form a black solid (1.735 g). Next, a partially cleaved fullerene nanomaterial 
was placed in a 100-mL flask and then 1,4-dioxane (18  mL) and concentrated hydro-
chloric acid (3  mL, 35%) were added (the black solid product immediately dissolved). 
The flask was tightly closed and the reaction mixture was allowed to proceed for further 
hydrolysis at room temperature for 7  days. The solvents were evaporated in vacuo to 
form a brown solid of compound 6 (2.092 g). The final product was purified by dialy-
sis of an aqueous solution of fullerene 6 using cellulose membranes (molecular weight 
exclusion limit 1.0 kDa; Spectrum Labs, USA). The dialysis lasted 7 days, and the final 
fullerene nanomaterial 6 was concentrated, frozen and lyophilized. The final product 
was obtained as a brown solid with a 35% yield (137.8 mg).
NanoC60GEM
In a small vial, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI, 6.60  mg, 
0.034  mmol), N-hydroxysuccinimide (NHS, 3.96  mg, 0.034  mmol) and fullerene 6 
(30.0 mg, 0.0014 mmol) were dissolved in 2 mL of a MES buffer (10% 2-(N-morpholino)
ethanesulfonic acid in water, pH = 4.5). After 5  min of stirring, the whole mixture 
was added (rinsing the vial twice with 0.5 mL of the MES buffer) into a reaction ves-
sel (10  mL) containing gemcitabine (GEM, 10.32  mg, 0.034  mmol). The [60]fullerene 
derivative 6 was dissolved instantly and the reaction vessel was placed on a magnetic 
stirrer at room temperature for 92 h. Afterwards, the final product was purified by dialy-
sis against an aqueous solution, using a cellulose membrane (10 mL, molecular weight 
exclusion limit 1.0 kDa; Spectrum Labs, USA). The dialysis lasted 10 days and the water 
was changed twice a day. Finally, the dialysate was concentrated, frozen and lyophilized. 
The final product was obtained as a brown solid with a 79% yield (29.42  mg) and its 
purity was confirmed by HPLC (Additional file 1: Fig. S7).
Time‑resolved singlet oxygen detection
Phosphate-buffered (pD 7.4, 10  mmol)  D2O solutions of  nanoC60-GEM and TMPyP 
in a 1-cm-optical path quartz fluorescence cuvette (QA-1000; Hellma, Mullheim, Ger-
many) was excited by light pulses that were generated by an integrated nanosecond DSS 
Nd:YAG laser system, equipped with a narrow bandwidth optical parametric oscillator 
(NT242-1k-SH/SFG; Ekspla, Vilnius, Lithuania). The laser system delivered pulses at 
a 1-kHz repetition rate, with a pulse energy up to several hundred microjoules in the 
visible region, and up to several tens of microjoules in the UVA–UVB region. The [60]
fullerene photosensitizers were photoexcited using a 427 nm wavelength. The absorb-
ance of the samples was set to 0.27 in that wavelength. In order to adjust the photoexci-
tation energy in the experiments, a laser beam was attenuated with three pieces of wire 
mesh (light transmission 40% each). The quantum yield of singlet oxygen formation was 
calculated using 5,10,15,20-tetrakis(1-methyl-4-pyridinio)porphyrin tetra(p-toluenesul-
fonate) (TMPyP) as the reference compound (φ = 0.75) (Snyder et al. 2006).
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Electron paramagnetic resonance spin trapping studies
EPR spin trapping was used with DMPO as the spin trap at a concentration of 
100 mM. Samples containing 0.1 mg/mL  nanoC60GEM in 80% DMSO were irradiated 
in EPR quartz flat cells in the resonant cavity with 402- to 508-nm (24 mW/cm2) light, 
which was produced by a 300-W high-pressure compact arc xenon lamp (Cermax, 
PE300CE13FM/Module300W; PerkinElmer Optoelectronics, GmbH, Wiesbaden, 
Germany). The irradiation setup was equipped with a water filter, heat reflecting hot 
mirror, cut-off filter that blocked light below 390 nm and a blue additive dichroic filter 
505FD64-25 (Andover Corporation, Salem, NH, USA).
Cell lines and culture methods
The human breast carcinoma; MCF-7 and human lung carcinoma epithelial-like A549 
were obtained from the American Type Culture Collection (ATCC). The human pan-
creas adenocarcinoma AsPc-1 and pancreatic carcinoma of a ductal origin PANC-1 
were obtained from Sigma-Aldrich. The murine pancreatic ductal adenocarcinoma; 
PAN02 was obtained from NCI-Frederick Cancer Research Facility and the normal 
human fibroblasts NHDF was obtained from PromoCell. The cell lines; MCF-7, A549, 
PANC-1 and NHDF were grown in Dulbecco’s modified Eagle’s medium (DMEM). 
The DMEM for MCF-7, A549 and PANC-1 were supplemented with 12% heat-inac-
tivated fetal bovine serum (Sigma) and for the NHDF with 15% non-inactivated fetal 
bovine serum (Sigma). The AsPc-1 and PAN02 cell lines were cultured in a RPMI 
1640 medium (Gibco, UK), which had been supplemented with 10% heat-inacti-
vated fetal bovine serum (Sigma). All of the culture media were supplemented with 
the antibiotics penicillin/streptomycin (Gibco) (1% v/v). The cell lines were grown as 
monolayer cultures in 75 cm2 flasks (Nunc) under standard conditions at 37  °C in a 
humidified atmosphere at 5%  CO2. All of the cell lines were tested for Mycoplasma 
contamination.
Cytotoxicity studies
The cells were seeded in 96-well plates (Nunc) at a density of 5 × 103 cells/well for the 
cancer cell lines and 4 × 103 cells/well for the normal cell line (NHDF) and incubated 
at 37  °C for 24 h. An MTS assay (CellTiter  96® AQueous One Solution Cell Prolifera-
tion Assay from Promega) was performed after a 72 h incubation of the cells using 
 nanoC60GEM (2–0.1  mg/mL) and gemcitabine (0.01–25  μM). The medium was then 
removed and 20 mL of a  CellTiter96®AQueousOne Solution-MTS (Promega) was added 
to each well (with 100 mL DMEM without phenol red) and incubated at least for 1 h 
at 37  °C. The absorbance of the samples was measured at 490 nm using a multi-plate 
reader (Synergy 4, BioTek). The results which were expressed as a percentage of the con-
trol were calculated as the inhibitory concentration  (IC50) values using GraphPad Prism 
7. Each experiment was repeated at least three times, each in triplicate.
Cell cycle assay
The PAN02 cells were seeded in 3  cm Petri dishes (Nunc) at a density of 1.5 × 105 
cells/dish and incubated at 37  °C for 24  h. Then, solutions of the  nanoC60GEM (35 
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and 17 μM) and gemcitabine (1.5 and 0.75 μM) were added. After a 48-h treatment, 
an assay was performed using a Muse Cell-Cycle Kit (Millipore) according to the 
manufacturer’s instructions. Briefly, the cells were collected, washed with cold PBS 
and centrifuged at 300g. Next, the cells were fixed in ice-cold 70% ethanol and stored 
at − 20 °C overnight. Afterwards, the cells were centrifuged and resuspended in 200 
μL of a Muse™ Cell Cycle Reagent and incubated for 30 min at room temperature in 
the dark. After staining, the cells were processed for the cell cycle analysis using a 
Muse Cell Analyzer (Millipore). The experiments were performed at least three times, 
each in triplicate.
Annexin V binding assay
The PAN02 cells were seeded in 3-cm Petri dishes (Nunc) at a density of 1,5 × 105 cells/
dish and incubated at 37 °C for 24 h. Then, solutions of the  nanoC60GEM (35 and 17 μM) 
and gemcitabine (1.5 and 0.75  μM) were added. After 48  h, an assay was performed 
using an Annexin V & Dead Cell Kit (Millipore) according to the manufacturer’s instruc-
tions. Briefly, both detached and adherent cells were collected and centrifuged at 500 g 
for 5 min. Afterwards, the resuspended cells were incubated with 100 μL of a Muse™ 
Annexin V & Dead Cell Reagent for 20  min at room temperature in the dark. After 
staining, the events for live, early and late apoptotic cells were counted using a Muse 
Cell Analyzer (Millipore). The experiments were performed at least three times, each in 
triplicate.
Photodynamic therapy on the PAN02 cell line
The PAN02 line cells were plated in 24-well plates at density of 35,000/well. Twenty-four 
hours after plating, the cells were incubated with high-glucose DMEM that contained 
 nanoC60GEM at different concentrations. Feeding was repeated two more times, at 24-h 
intervals. The day after the final feeding the cells were washed twice with PBS that con-
tained calcium and magnesium ions, then irradiated for 15  min using a blue led light 
(440 nm) at a fluence rate 20 mW/cm2. Dark control cells were kept in the same condi-
tions except light exposure. After irradiation, the cells were provided with DMEM with 
10% FBS. The cytotoxic effect of the photodynamic treatment was quantified 24 h after 
irradiation, using a MTT assay for the mitochondrial redox function. The MTT solution 
in DMEM with 10% FBS was added to the treated and control culture wells (final con-
centration of 0.5 mg/mL). After incubation for 30 min at 37 °C, the culture medium was 
removed and the remaining blue precipitate was solubilized in DMSO, followed by read-
ing the absorbance at 560 nm in a plate reader (GENios Plus, Tecan Austria GmbH). The 
results are reported as the percentage of the paired untreated controls. The experiments 
were repeated a minimum of three times.
Statistical analysis
The results are expressed as the mean ± standard deviation (SD) from at least three inde-
pendent experiments. A statistical analysis was performed using the one-way ANOVA 
with a Bonferroni post hoc test. A p value of 0.05 or less was considered to be statisti-
cally significant. GraphPad Prism v.7.0 software (GraphPad Software, USA) was used for 
the analysis (Fig. 1).
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Results and discussion
Synthetic protocol and characterization of  nanoC60GEM
The synthetic protocol for obtaining  nanoC60GEM is shown in Scheme 1. During our 
design step, we decided to use a glycine derivative of malonic acid 1 as the substrate for 
the Bingel–Hirsch reaction. We expected that the carboxylic groups, which are present 
in that compound would be much more reactive toward the aromatic amines (i.e., the 
cytosine fragment in the gemcitabine) in contrast to the malonic acid derivatives, which 
are closely connected the [60]fullerene scaffold, based on literature findings (Wang et al. 
2015). The desired [60]fullerene monoadduct 4 was created in a high yield by in situ gen-
eration of α-brominated malonate 2 in the presence of  CBr4/DBU at room temperature 
in a time-controlled reaction, where monoadducts were formed up to 3  h. However, 
after that time, bis- and tris-adducts formed, which made the purification process more 
complicated. The structure of the monoadduct 4 was confirmed using MALDI-TOF 
spectrometry with a characteristic peak at 992 Da and no presence of the bis- or tris-
adducts (Additional file  1: Fig. S1). The second Bingel–Hirsh reaction was performed 
using diserinol malonate acetate (malonate 3) in order to ensure a high degree of water 
solubility and the desired hexakis adduct with Th symmetry was created (compound 5) 
in a good yield. The deprotection of fullerene 5 was performed in a two-step procedure, 
which involved hydrogenolysis with sodium hydride first and then the final hydrolysis 
with 1,4-dioxane with concentrated HCl added. The molecular peak of the [60]fullerene 
derivative 6 is shown in Additional file 1: Fig. S2 with the characteristic mass of 2195 Da 
[M + H2O + H]+ and no signals from the pentakis isomer. The final step of the conjuga-
tion with GEM was performed using the water-soluble carbodiimide EDCI/NHS sys-
tem in a solution of a MES buffer. The ESI spectrometry confirmed the formation of the 
desired  nanoC60GEM (Additional file 1: Fig. S3) which had a characteristic signal of the 
molecular peak at 2690 Da [M + Na]+, which represented the [60]fullerene derivative 6 
that had been conjugated to two molecules of gemcitabine via an amide bond. Interest-
ingly, a fragmentation pattern, in which one serinol group left the  nanoC60GEM (charac-
teristic at 2578 Da, Additional file 1: Fig. S3), was observed.
The UV–VIS spectrum of  nanoC60GEM is characteristic for the water-soluble fuller-
enes that have a high absorbance only in the UV and blue regions of a spectrum (max 
absorbance was observed at 220 nm). Moreover, we found that  nanoC60GEM tends to 
form monodisperse aggregates around 120  nm as was confirmed by DLS (Additional 
Fig. 1 Chemical structure of  nanoC60‑GEM
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file 1: Fig. S4), and which may be disintegrated into smaller individual fullerenes inside 
the cell (Lapin et al. 2017b). The zeta potential measurements of our gemcitabine nano-
conjugate (Additional file 1: Fig. S5) also indicated a surface charge of − 25 mV, thus con-
firming a relatively good degree of stability.
The infrared spectrum of the  nanoC60GEM system  was divided into two spectral 
regions: (1) 2700–3800  cm−1 and (2) 700–1850  cm−1 (Fig.  2). The high wavenum-
ber region is characterized by the presence of a broadened band that is centered at 
3364 cm−1, which corresponded to the overlapping signal that had originated from the 
Scheme 1 Synthetic pathway for obtaining  nanoC60GEM
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hydroxyl (Motoyama and Jarboe 1966) and the secondary amide vibration (Lumley Jones 
1963). The observable band shift toward a lower wavenumber, especially in relation to 
the hydroxyl group, may have resulted from the formation of an inter- or intramolecular 
hydrogen bonding scheme. In turn, the low-wavenumber bands with their maxima cen-
tered at 2927 and 2841 cm−1 may have originated from the asymmetric and symmetric 
stretching mode of the methylene groups that overlapped with the stretching vibration 
of the CH moieties.
The fingerprint (1) region, especially at high wavenumbers with a maxima located at 
1790, 1724 and 1678 cm−1, is determined by the carbonyl stretching modes due to pri-
mary amides (Craig and Evans 1965). The deformational mode of the secondary amide 
could have corresponded to the band at 1535 cm−1. In addition, this band has a combi-
nation character with vibration originated from the medium–strong vibration within the 
furan (Katritzky and Lagowski 1959) as well as the C=C and C=N ring stretching vibra-
tions within the pyrimidin-2-one (Billes et al. 1998). The other low-intense bands with 
their maxima at 1371 and 1248  cm−1 were mainly linked to the deformational modes 
of the methylene groups that were located within the aliphatic chain or the furan and 
pyrimidin-2-one rings. In turn, the interpretation of the band at 1048 cm−1 was unam-
biguous because of the overlapping character of the various modes that may be acti-
vated at this wavenumber such as a C=C–H deformation within the aliphatic moieties 
or within the furan and pyrimidin-2-one, the CN of a secondary amine or asymmetric 
and symmetric vibration of the CF. In turn, the deformational mode of the CF could 
have been expected at 726 cm−1. Finally, one can summarize that the band arrangement 
indicated on the presence of the hydroxyl, secondary amine, and fluorine substituents, 
which confirmed that the synthesis had been performed successfully.
The chemical states of the elements that were present on a sample surface were 
analyzed using XPS. The change in the binding energy was related to changes in the 
chemical bonding with the surrounding elements. An analysis of the carbon chemical 
states was performed to analyze the C1s core level. A resolved line, see Fig. 3a, indi-
cates the presence of several different chemical states of the carbon. The state with 
the lowest binding energy of 282.84 eV was associated with the presence of an impu-
rity of an SiC origin. The amount of this state was relatively low about 4.19% of the 
entire amount of carbon (see Additional file  1: Table  S1). The highest peak, which 
Fig. 2 a Infrared spectrum of nanoconjugate measured in the 700–4000 cm−1 range. b UV–VIS spectrum of 
 nanoC60GEM recorded in ultrapure water (c = 0.01 mg/mL)
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was located at 284.71 eV, indicates the presence of C–C and C–H type bonds (Watts 
1993). The peak centered at 286.33 eV could be assigned to the C–O and C–N bonds 
and has been the case for other fullerene derivatives (Yu et al. 2012), whereas the peak 
at 287.74 eV corresponds to the states that have been observed in poly(vinyl fluoride) 
(Clark et  al. 1973) or fluorobenzene (Clark et  al. 1972) compounds. Fluorine analy-
sis was difficult, mainly due to the quality of the spectrum, which resulted from the 
small amount of this element in the sample. Calculations of the atomic concentration 
indicated about 0.06 atomic percent of F on the sample surface, which is generally the 
detection limit of the XPS technique.
Nevertheless the fluorine 1s photoemission line had (see Fig.  3b) a peak that was 
located at 687.63 eV, and similar values were observed for graphite fluorides for which 
the peaks located in the range of 687–689 eV were assigned to the adsorbed fluorine 
(Palchan et al. 1989). The weakly developed peak at 687.63 eV may be associated with 
polyvinylidene fluoride (PVDF); however, as this state represents only 7% of all of the 
fluorine, which is itself a trace element, the analysis could not be precise. An analysis 
of oxygen confirmed what had been observed in the C1s C–O bonds. For nitrogen, 
the N1s line indicated the presence of two chemical states, one weakly developed at 
397.57 eV, which was related to the  Si3N4 compound and the second of high intensity 
Fig. 3 The XPS high‑resolution photoemission lines of  nanoC60‑GEM: a carbon C1s, and b fluorine F1s
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at 399.78 eV, which was related to the bonds that present in nylon. In the case of sili-
cone, two chemical states were also present, one was centered at 100.33 eV and was 
related to SiC and the second at 102.02 eV, which was related to  Si3N4. Additionally, 
a small amount of bromine was observed and was associated with AgBr. Taking into 
account the atomic concentrations, which were calculated from the XPS measure-
ments, in which the amount of carbon was approximately 79.39 at.%, oxygen 15.36 
at.%, nitrogen 3.89 at.%, fluorine 0.06 at.%, silicone 1.14 at.%, and bromine 0.15 at.%, 
both the Si and Br can be treated as trace elements that appeared due to synthetic 
impurities or sample preparation.
Biophysical characterization of  nanoC60GEM
The water-soluble [60]fullerene nanomaterials are well-known for their ability to pro-
duce different types of reactive oxygen species when irradiated by blue light (Mroz et al. 
2007).
Based on previous literature studies, in polar solvents, in particular those contain-
ing donor electrons such as NADH, the irradiation of fullerenes leads to the generation 
of reduced oxygen species, such as superoxide anion radical (O2•−) and hydroxyl radi-
cal (OH•). In non-polar solvents such as benzene, the process of singlet oxygen (1O2) is 
primarily formed (Yamakoshi et al. 2003). UV light has a very low ability to penetrate 
through tissue and can cause a non-specific effect in any cells it hits. In our study, we 
used blue LED light, which has a slightly better tissue penetration that does not cause 
any damage to cells that have no photosensitizer. The photoreactivity of the analyzed 
fullerene nanoparticles was determined by measuring their ability to generate, after irra-
diation with blue LED light, singlet oxygen and superoxide anion, which may have oxi-
dizing effects on several cellular targets, especially under conditions with a low-oxygen 
concentration. In this study, we carried out singlet oxygen photogeneration studies of 
 nanoC60GEM using a cationic porphyrin (TMPyP) as the reference photosensitizer.
The calculated quantum efficiency of 1O2 formation for our water-soluble [60]fullerene 
derivative, which had been irradiated by blue LED light was around 0.05. Although the 
efficacy of singlet oxygen formation for pristine fullerene is almost at unity (at 532 nm), 
chemical modifications can decrease their efficacy (Arbogast et al. 1991). Earlier stud-
ies with Bingel–Hirsch products confirmed the observation that monoadducts as well 
as aminofullerenes produce singlet oxygen more effectively than hexakis adducts (as 
 nanoC60GEM) (Hamblin 2018). More importantly, we discovered that in the presence of 
bovine serum albumin (100 mM) this process is reduced, suggesting a close interaction 
between fullerene and the formation of the protein corona (Fig. 4c).
We also measured superoxide photogeneration using the EPR spin-trapping method 
with DMPO as the spin trap. While  nanoC60GEM alone showed a negligible signal of 
trapped adducts, the presence of electron donor (NADH) increased the signal by an 
order of magnitude (Fig.  4b), thus showing that in favorable conditions, the electron 
transfer route may also contribute to a phototoxic effect. Spin trapping was performed 
in 80% DMSO, which made any measurements in the presence of BSA impossible as it 
would have destroyed the protein structure. Although the photoreactivity of our novel 
fullerene nanomaterial is not very high, its localization within cancer cells could make it 
more phototoxic if it is localized, for example, in the nucleus (Serda et al. 2018).
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Fig. 4 Photoreactivity of  nanoC60GEM. a Quantum yield of singlet oxygen generation after irradiation by 
blue LED light by  nanoC60GEM with TMPyP used as the reference photosensitizer; b spin adduct signal 
(DMPO‑OOH) that was formed in the absence and presence of an electron donor (0.5 mM NADH) after blue 
LED light irradiation; c 1270 nm luminescence observed in the absence and presence (100 µM) of bovine 
serum albumin
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Biology
Cytotoxicity
We performed cytotoxicity screening using several cancer cell lines of different origins 
including normal human fibroblasts. During the biological studies, we decided to study 
pancreatic, breast and lung cancers because of the clinical use of GEM for the aforemen-
tioned neoplasms (Xie et al. 2018; Watanabe et al. 2019). The calculated  IC50 values are 
presented in Table 1.
We observed a noticeable cytotoxicity for two cell lines, MCF-7 and PAN02, for which 
we calculated the  IC50 parameters to be 2.07 ± 0.64 and 7.35 ± 1.13  µM, respectively. 
Compared to gemcitabine alone, the cytotoxic effect was reduced. A possible expla-
nation of this phenomenon may be the ineffective transport of  nanoC60GEM into the 
nucleus. Gemcitabine is a deoxycytidine analog with two additional fluoride atoms and 
as nucleoside derivative, it is transported throughout human nucleoside transporters 
(hNTs) (Mackey et al. 1998).
We hypothesized that after GEM was conjugated with [60]fullerene, this type of trans-
port would be unavailable. Additionally, GEM is incorporated into the C60 structure 
by the formation of an amide bond which, for steric hindrance, is probably difficult to 
access through the cellular enzymes such as proteases. Despite its higher activity toward 
the MCF-7 cell line, we selected the PAN02 cell line for the further studies because we 
also wanted to perform in vivo studies.
Cell cycle
In order to evaluate the mechanism of action of  nanoC60GEM, we performed a flow 
cytometry measurement. As is presented in Fig.  5, after 48  h of the incubation with 
 nanoC60GEM and gemcitabine, we observed a decrease in the faction of cells in the G0/
G1 phase (compared to the control). However, there was an increase in the number of 
cells in the S phase in all of the cases that were examined regardless of the concentration. 
This increase indicated an inhibition of the cell cycle in the S phase. This is consistent 
with Huang’s studies for gemcitabine (Huang et al. 1991), which indicates that it inhibits 
DNA synthesis. After its uptake into a cell, gemcitabine is metabolized into an active 
triphosphate form. Thereafter, this form is embedded in the DNA chain, thereby pre-
venting its elongation.
Cell death
In order to determinate the type of the cell death, we also used flow cytometry. In this 
experiment, after 48 h of incubation with  nanoC60GEM and gemcitabine, we measured 
the green signal that was derived from apoptotic cells. As is presented in Fig.  6, the 
Table 1 Antiproliferative activity of the studied compounds
The  IC50 parameters were calculated using GraphPad Prism 7
Compound IC50 [µM]
MCF‑7 AsPc‑1 PAN02 PANC‑1 A549 NHDF
NanoC60GEM 2.07 ± 0.64 > 375 7.35 ± 1.13 > 375 > 375 > 375
Gemcitabine 0.044 ± 0.008 0.207 ± 0.046 0.027 ± 0.003 21.95 ± 3.99 > 25 > 25
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biggest fraction of the apoptotic cell was detected for gemcitabine (44% compared to 
the control). There was no big difference between the two concentrations of GEM (0.75 
and 1.5 µM) that were tested. However, for  nanoC60GEM, we also registered a compa-
rable population of apoptotic cells (38.6% for 35 µM of  nanoC60GEM). These results are 
promising from the perspective of further studies.
Phototoxicity studies
According to research reports, [60]fullerene derivatives have a great potential 
to be used as photosensitizers in photodynamic therapy. In order to evaluate this 
hypothesis, we performed experiments in which the cells were incubated with 
 nanoC60GEM for 3  days to cause the cellular nucleases to cleave GEM from the 
nanoconjugate, after which the cells were irradiated with blue LED light. After the 
Fig. 5 Effect of the tested  nanoC60GEM (35 and 17 µM) and GEM (1.5 and 0.75 µM) on regulating the cell 
cycle in the PAN02 cell line. The histograms show the distribution of the cells in the G0/G1, S and G2/M 
phases of the cell cycle for an exemplary experiment (a). The table shows the mean ± SD percentage of the 
cells in the G0/G1, S and G2/M phases of the cell cycle from three independent experiments (b). The data 
were analyzed using a one‑way ANOVA with a Bonferroni’s post hoc test: *p < 0.05, **p < 0.01, ***p < 0.001 
compared to the control (c)
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irradiation a cell viability assay was performed (24  h, MTT). The selection of the 
correct wavelength (440 nm) to be used was dictated by the absorption properties 
of the studied nanomaterial (Fig. 2b), in order to avoid UV part of the spectrum that 
could cause unspecific effects. As is depicted in Additional file 1: Fig. S4, the tested 
Fig. 6 Evaluation of the induction of apoptosis in the PAN02 cell line after a 48‑h treatment with 
 nanoC60GEM (35 and 17 µM) and GEM (1.5 and 0.75 µM). The histograms show the percentage of early and 
late apoptosis for one of the experiments (a). The table shows the mean ± SD percentage of the live, early 
and late apoptotic cells from three independent experiments (b). The data were analyzed using one‑way 
ANOVA with a Bonferroni’s post hoc test: *p < 0.05, **p < 0.01, ***p < 0.001 compared to the control (c)
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compound did not generate a significant level of the singlet oxygen and superoxide 
anion. Addition of an electron donor increased the superoxide production many-
fold (Fig. 4b), but such favorable conditions are difficult to find in a cellular envi-
ronment. Therefore, we conducted the experiments by adding BSA (Fig. 4c), which 
confirmed the interaction of the fullerene nanomaterial and the formation of the 
protein corona. Our results show that the interaction with conducts serum protein 
leads to a decrease in the observable signal of singlet oxygen, which may be caused 
by a decreased yield of the generation or by an increased quenching of the singlet 
oxygen by bounded proteins. To explore this issue in depth, we performed in vitro 
studies using a medium that contained FBS. The results, which are presented in 
Fig.  7, confirmed the non-toxic properties of the low concentrations of irradiated 
 nanoC60GEM, which reduced the chances of using this type of fullerene nanomate-
rial as a photosensitizer. Although the PAN02 cell line phototoxicity response was 
disappointing, we plan to study the effects of  nanoC60GEM on different cancer cell 
lines and 3D-spheroids.
Conclusions
The developed synthetic protocol was able to produce a highly water-soluble 
[60]fullerene nanoconjugate with gemcitabine in good yield. The physio-chemi-
cal characteristics of the fullerene nanomaterial confirms that two gemcitabine 
units are attached to the [60]fullerene scaffold via formation of amide bonds. The 
 nanoC60GEM cytotoxicity effect was dependent on its concentration in PAN02 cells, 
but its phototoxic effects were mild, partly due to the formation of the protein corona 
on the surface of the [60]fullerene scaffold as well as the low quantum yields of the 
singlet oxygen generation. Further biological studies using 3D-spheroids as well as 
murine models should be used in order to evaluate the efficacy of a therapy using 
 nanoC60GEM.
Fig. 7 Phototoxicity of  nanoC60GEM performed for the PAN02 cancer cell line
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